Scott Coleman
Corporate Officer/Principal bei XILIO THERAPEUTICS, INC.
Profil
Scott Coleman is currently the Chief Development Officer at Xilio Therapeutics, Inc. He previously worked as the Vice President-Non-Clinical Development at Acceleron Pharma, Inc. Dr. Coleman holds a doctorate degree from North Carolina State University and an undergraduate degree from Northeastern University.
Aktive Positionen von Scott Coleman
| Unternehmen | Position | Beginn |
|---|---|---|
| XILIO THERAPEUTICS, INC. | Corporate Officer/Principal | 01.06.2022 |
Ehemalige bekannte Positionen von Scott Coleman
| Unternehmen | Position | Ende |
|---|---|---|
| ACCELERON PHARMA INC. | Corporate Officer/Principal | - |
Ausbildung von Scott Coleman
| North Carolina State University | Doctorate Degree |
| Northeastern University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| XILIO THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Acceleron Pharma, Inc.
 Acceleron Pharma, Inc. BiotechnologyHealth Technology Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA. | Health Technology |
